Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.

Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo

Open access

Abstract

Brains of Alzheimer's disease patients are characterized by the presence of amyloid plaques and neurofibrillary tangles, both invariably associated with neuroinflammation. A crucial role for NLRP3-ASC inflammasome [NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-Apoptosis-associated speck-like protein containing a CARD (ASC)] in amyloid-beta (Aβ)-induced microgliosis and Aβ pathology has been unequivocally identified. Aβ aggregates activate NLRP3-ASC inflammasome (Halle et al. in Nat Immunol 9:857-865, 2008) and conversely NLRP3-ASC inflammasome activation exacerbates amyloid pathology in vivo (Heneka et al. in Nature 493:674-678, 2013), including by prion-like ASC-speck cross-seeding (Venegas et al. in Nature 552:355-361, 2017). However, the link between inflammasome activation, as crucial sensor of innate immunity, and Tau remains unexplored. Here, we analyzed whether Tau aggregates acting as prion-like Tau seeds can activate NLRP3-ASC inflammasome. We demonstrate that Tau seeds activate NLRP3-ASC-dependent inflammasome in primary microglia, following microglial uptake and lysosomal sorting of Tau seeds. Next, we analyzed the role of inflammasome activation in prion-like or templated seeding of Tau pathology and found significant inhibition of exogenously seeded Tau pathology by ASC deficiency in Tau transgenic mice. We furthermore demonstrate that chronic intracerebral administration of the NLRP3 inhibitor, MCC950, inhibits exogenously seeded Tau pathology. Finally, ASC deficiency also decreased non-exogenously seeded Tau pathology in Tau transgenic mice. Overall our findings demonstrate that Tau-seeding competent, aggregated Tau activates the ASC inflammasome through the NLRP3-ASC axis, and we demonstrate an exacerbating role of the NLRP3-ASC axis on exogenously and non-exogenously seeded Tau pathology in Tau mice in vivo. The NLRP3-ASC inflammasome, which is an important sensor of innate immunity and intensively explored for its role in health and disease, hence presents as an interesting therapeutic approach to target three crucial pathogenetic processes in AD, including prion-like seeding of Tau pathology, Aβ pathology and neuroinflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-018-01957-y

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pre-aggregated Tau seeds activate NLRP3–ASC inflammasome microglia following endo-lysosomal sorting. a Schematic presentation of the NLRP3–ASC inflammasome pathway indicating the experiments used to interfere with this pathway to study the pathway of NLRP3–ASC inflammasome activation by Tau seeds (some of the graphical elements were adapted from Servier Medical Art—https://smart.servier.com/). b (1) Measurements of IL-1β concentrations in the medium of primary microglia following the addition of buffer (control), LPS, LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau) demonstrate strong induction of IL-1β secretion by the latter two conditions (three independent experiments, n = 3 per experiment and per condition; one-way ANOVA with Dunnett’s multiple comparison post hoc test compared to control, ***p value < 0.001, ****p < 0.0001). b (2) Measurements of IL-1β concentrations in the medium of primary microglial cultures following addition of buffer (control), LPS, LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau); ASC +/− and ASC +/+ primary microglial cultures demonstrates gene-dosage dependent induction of IL-1β, while induction in ASC−/− microglia is strongly inhibited (three independent experiments, n = 3 per experiment and per condition; two-way ANOVA with Dunnett’s multiple comparison post hoc test; LPS + Nig: ASC +/+ vs ASC−/−, ****p < 0.0001; ASC +/+ vs ASC +/– , ***p value < 0.001; LPS + Tau: ASC +/+ vs ASC−/−, ****p < 0.0001; ASC +/+ vs ASC +/– , **p value < 0.01). b (3) Measurements of IL-1β concentrations in the medium of primary microglia in control conditions (control) and following addition of buffer only (buffer), LPS, LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau), in the absence (blue lines) or presence of MCC950 (red lines), a pharmacological inhibitor of NLRP3 inflammasome, demonstrate strong induction of IL-1β secretion by the latter two conditions in the absence of MCC950, while induction of IL-1β secretion in the presence of MCC950 is strongly inhibited. This indicates the dependence on NLRP3 activation. Measurements of IL-1β concentrations in the presence and absence of Cathepsin B inhibitor (CA-074 Me) (orange lines) demonstrates strong induction of IL-1β secretion in the medium of primary microglia following addition of LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau) in the absence of the cathepsin B inhibitor, while induction of IL-1β secretion in the presence of cathepsin inhibitor is strongly inhibited for LPS + Tau seeds. This indicates the dependence of NLRP3–ASC inflammasome activation by Tau seeds on cathepsin B activity (three independent biological experiments; n = 3 or 2 samples per experiment and per condition; two-way ANOVA with Tukey’s multiple comparison post hoc test; ****p < 0.0001). c Immunocytological analysis reveals strong co-localization of Tau seeds and microglial cells, respectively, stained with anti-myc antibody (green) and with anti-LAMP1 antibody (red), a lysosomal marker. This demonstrates uptake of Tau seeds and sorting to lysosomal compartments
Fig. 1 Pre-aggregated Tau seeds activate NLRP3–ASC inflammasome microglia following endo-lysosomal sorting. a Schematic presentation of the NLRP3–ASC inflammasome pathway indicating the experiments used to interfere with this pathway to study the pathway of NLRP3–ASC inflammasome activation by Tau seeds (some of the graphical elements were adapted from Servier Medical Art—https://smart.servier.com/). b (1) Measurements of IL-1β concentrations in the medium of primary microglia following the addition of buffer (control), LPS, LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau) demonstrate strong induction of IL-1β secretion by the latter two conditions (three independent experiments, n = 3 per experiment and per condition; one-way ANOVA with Dunnett’s multiple comparison post hoc test compared to control, ***p value < 0.001, ****p < 0.0001). b (2) Measurements of IL-1β concentrations in the medium of primary microglial cultures following addition of buffer (control), LPS, LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau); ASC +/− and ASC +/+ primary microglial cultures demonstrates gene-dosage dependent induction of IL-1β, while induction in ASC−/− microglia is strongly inhibited (three independent experiments, n = 3 per experiment and per condition; two-way ANOVA with Dunnett’s multiple comparison post hoc test; LPS + Nig: ASC +/+ vs ASC−/−, ****p < 0.0001; ASC +/+ vs ASC +/– , ***p value < 0.001; LPS + Tau: ASC +/+ vs ASC−/−, ****p < 0.0001; ASC +/+ vs ASC +/– , **p value < 0.01). b (3) Measurements of IL-1β concentrations in the medium of primary microglia in control conditions (control) and following addition of buffer only (buffer), LPS, LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau), in the absence (blue lines) or presence of MCC950 (red lines), a pharmacological inhibitor of NLRP3 inflammasome, demonstrate strong induction of IL-1β secretion by the latter two conditions in the absence of MCC950, while induction of IL-1β secretion in the presence of MCC950 is strongly inhibited. This indicates the dependence on NLRP3 activation. Measurements of IL-1β concentrations in the presence and absence of Cathepsin B inhibitor (CA-074 Me) (orange lines) demonstrates strong induction of IL-1β secretion in the medium of primary microglia following addition of LPS + nigericin (LPS + Nig) and LPS + Tau seeds (LPS + Tau) in the absence of the cathepsin B inhibitor, while induction of IL-1β secretion in the presence of cathepsin inhibitor is strongly inhibited for LPS + Tau seeds. This indicates the dependence of NLRP3–ASC inflammasome activation by Tau seeds on cathepsin B activity (three independent biological experiments; n = 3 or 2 samples per experiment and per condition; two-way ANOVA with Tukey’s multiple comparison post hoc test; ****p < 0.0001). c Immunocytological analysis reveals strong co-localization of Tau seeds and microglial cells, respectively, stained with anti-myc antibody (green) and with anti-LAMP1 antibody (red), a lysosomal marker. This demonstrates uptake of Tau seeds and sorting to lysosomal compartmentsCC BY · PubMed Central
Fig. 2 ASC deficiency reduces induction of Tau pathology following exogenous Tau seeding in Tau transgenic mice. Immunohistological analysis of Tau pathology using anti-P-Tau (AT8) antibody in brains of T +. ASC +/+ and T +.ASC−/− mice. Tau seeding was performed at 3 months of age and analyzed 6 months post-seeding. Representative images of AT8 staining (red) in frontal cortex in T +.ASC +/+ and T +.ASC−/− mice are presented. Quantitative analysis of the area stained with AT8 reveals a significantly lower induction of Tau pathology in T +.ASC−/− compared to T +.ASC +/+ mice (n = 7, T +.ASC +/+; n = 5, T +.ASC−/−; Mann–Whitney t test; **p < 0.01). Silver staining (black) and ThioS (green) staining demonstrate the presence of mature NFTs following Tau seeding in Tau transgenic mice, representative images of frontal cortex are shown. Tau-seeding induced Tau pathology (NFTs) assessed by silver and ThioS staining was significantly less in T +.ASC−/− compared to T +.ASC +/+ mice (n = 7, T +.ASC +/+; n = 5, T +.ASC−/−; Mann–Whitney t test; *p < 0.05, **p < 0.01). These data confirmed an independent pilot study performed prior to this study to explore the potential effect of ASC deficiency on Tau-seeded Tau pathology, using Tau seeding in T +.ASC−/− compared to T +.ASC +/+ mice, demonstrating significantly inhibited Tau pathology following Tau seeding in ASC-deficient Tau mice (Online Resource 2)
Fig. 2 ASC deficiency reduces induction of Tau pathology following exogenous Tau seeding in Tau transgenic mice. Immunohistological analysis of Tau pathology using anti-P-Tau (AT8) antibody in brains of T +. ASC +/+ and T +.ASC−/− mice. Tau seeding was performed at 3 months of age and analyzed 6 months post-seeding. Representative images of AT8 staining (red) in frontal cortex in T +.ASC +/+ and T +.ASC−/− mice are presented. Quantitative analysis of the area stained with AT8 reveals a significantly lower induction of Tau pathology in T +.ASC−/− compared to T +.ASC +/+ mice (n = 7, T +.ASC +/+; n = 5, T +.ASC−/−; Mann–Whitney t test; **p < 0.01). Silver staining (black) and ThioS (green) staining demonstrate the presence of mature NFTs following Tau seeding in Tau transgenic mice, representative images of frontal cortex are shown. Tau-seeding induced Tau pathology (NFTs) assessed by silver and ThioS staining was significantly less in T +.ASC−/− compared to T +.ASC +/+ mice (n = 7, T +.ASC +/+; n = 5, T +.ASC−/−; Mann–Whitney t test; *p < 0.05, **p < 0.01). These data confirmed an independent pilot study performed prior to this study to explore the potential effect of ASC deficiency on Tau-seeded Tau pathology, using Tau seeding in T +.ASC−/− compared to T +.ASC +/+ mice, demonstrating significantly inhibited Tau pathology following Tau seeding in ASC-deficient Tau mice (Online Resource 2)CC BY · PubMed Central
Fig. 3 Pharmacological inhibition of the inflammasome reduces Tau pathology induced by Tau seeding in Tau transgenic mice, demonstrating therapeutic potential and NLRP3 inflammasome involvement. Immunohistological analysis of Tau pathology in brains of Tau transgenic mice 7 weeks post-Tau seeding. Tau seeding was performed at 3 months of age and analyzed 7 weeks post-seeding. Tau mice were chronically treated with a final concentration of 0.1 µM MCC950, 0.5 µM MCC950 and with PBS using osmotic mini-pumps for 7 weeks. Representative images of anti-P-Tau (AT8; red) staining in frontal cortex in chronically treated mice with 0.1 µM MCC950, with 0.5 µM MCC950 and with PBS, reveal significantly reduced Tau pathology in 0.5 µM MCC950-treated mice compared to PBS-treated mice. Quantitative analysis of the area stained with AT8 reveals a significantly lower induction of Tau pathology in 0.5 µM MCC950-treated mice compared to PBS-treated mice (n = 8, PBS; n = 8, 0.1 µM MCC950; n = 6, 0.5 µM MCC950; one-way ANOVA Dunnett’s multiple comparison; 0.1 µM MCC950 vs. PBS, p = 0.0630; 0.5 µM MCC950 vs. PBS, *p < 0.05). Silver (black) and ThioS (green) staining demonstrate the presence of mature NFTs following Tau seeding in Tau transgenic mice; representative images of frontal cortex are shown. Silver and ThioS staining showed significantly less Tau-seeding induced Tau pathology following 0.5 µM MCC950 treatment compared to PBS (n = 8, PBS; n = 8, 0.1 µM MCC950; n = 6, 0.5 µM MCC950; one-way ANOVA Dunnett’s multiple comparison; ThioS: 0.5 µM MCC950 vs. PBS, ****p < 0.0001; ThioS: 0.1 µM MCC950 vs. PBS, ***p < 0.001; silver: 0.5 µM MCC950 vs. PBS, *p < 0.05; silver: 0.1 µM MCC950 vs. PBS p = 0.0681)
Fig. 3 Pharmacological inhibition of the inflammasome reduces Tau pathology induced by Tau seeding in Tau transgenic mice, demonstrating therapeutic potential and NLRP3 inflammasome involvement. Immunohistological analysis of Tau pathology in brains of Tau transgenic mice 7 weeks post-Tau seeding. Tau seeding was performed at 3 months of age and analyzed 7 weeks post-seeding. Tau mice were chronically treated with a final concentration of 0.1 µM MCC950, 0.5 µM MCC950 and with PBS using osmotic mini-pumps for 7 weeks. Representative images of anti-P-Tau (AT8; red) staining in frontal cortex in chronically treated mice with 0.1 µM MCC950, with 0.5 µM MCC950 and with PBS, reveal significantly reduced Tau pathology in 0.5 µM MCC950-treated mice compared to PBS-treated mice. Quantitative analysis of the area stained with AT8 reveals a significantly lower induction of Tau pathology in 0.5 µM MCC950-treated mice compared to PBS-treated mice (n = 8, PBS; n = 8, 0.1 µM MCC950; n = 6, 0.5 µM MCC950; one-way ANOVA Dunnett’s multiple comparison; 0.1 µM MCC950 vs. PBS, p = 0.0630; 0.5 µM MCC950 vs. PBS, *p < 0.05). Silver (black) and ThioS (green) staining demonstrate the presence of mature NFTs following Tau seeding in Tau transgenic mice; representative images of frontal cortex are shown. Silver and ThioS staining showed significantly less Tau-seeding induced Tau pathology following 0.5 µM MCC950 treatment compared to PBS (n = 8, PBS; n = 8, 0.1 µM MCC950; n = 6, 0.5 µM MCC950; one-way ANOVA Dunnett’s multiple comparison; ThioS: 0.5 µM MCC950 vs. PBS, ****p < 0.0001; ThioS: 0.1 µM MCC950 vs. PBS, ***p < 0.001; silver: 0.5 µM MCC950 vs. PBS, *p < 0.05; silver: 0.1 µM MCC950 vs. PBS p = 0.0681)CC BY · PubMed Central
Fig. 4 Tau-seeding induced microgliosis is decreased in ASC-deficient Tau mice. a Representative images of immunohistological staining using Iba1 (green) and anti-P-Tau (AT8; red) following Tau seeding in frontal cortex of T +.ASC-/- and T +. ASC +/+ mice are presented. Quantitative analysis of anti-Iba1 staining demonstrates lower microglial activation in T +. ASC−/− compared to T +.ASC +/+ mice (n = 7 T +.ASC +/+ and n = 5 T +.ASC−/− mice; Mann–Whitney t test; *p < 0.05). b Representative images of immunohistological staining using Iba1 (green) and AT8 (red) following Tau seeding in mice chronically treated with PBS or with 0.5 µM MCC950 for 7 weeks are presented. Quantitative analysis of anti-Iba1 staining demonstrates lower microglial activation upon exogenous Tau seeding in the presence of chronic 0.5 µM MCC950 treatment compared to PBS treatment in Tau transgenic mice (n = 8, PBS treated; n = 6, 0.5 µM MCC950 treated; Mann–Whitney t test; *p < 0.05)
Fig. 4 Tau-seeding induced microgliosis is decreased in ASC-deficient Tau mice. a Representative images of immunohistological staining using Iba1 (green) and anti-P-Tau (AT8; red) following Tau seeding in frontal cortex of T +.ASC-/- and T +. ASC +/+ mice are presented. Quantitative analysis of anti-Iba1 staining demonstrates lower microglial activation in T +. ASC−/− compared to T +.ASC +/+ mice (n = 7 T +.ASC +/+ and n = 5 T +.ASC−/− mice; Mann–Whitney t test; *p < 0.05). b Representative images of immunohistological staining using Iba1 (green) and AT8 (red) following Tau seeding in mice chronically treated with PBS or with 0.5 µM MCC950 for 7 weeks are presented. Quantitative analysis of anti-Iba1 staining demonstrates lower microglial activation upon exogenous Tau seeding in the presence of chronic 0.5 µM MCC950 treatment compared to PBS treatment in Tau transgenic mice (n = 8, PBS treated; n = 6, 0.5 µM MCC950 treated; Mann–Whitney t test; *p < 0.05)CC BY · PubMed Central
Fig. 5 Age-dependent increase in microglial activation in Tau transgenic mice and decreased Tau pathology in ASC-deficient Tau mice indicate a contribution of the inflammasome in non-exogenously seeded Tau pathology. a Representative images of Iba1 (green) and anti-P-Tau (AT8; red) staining in hippocampal CA1 region of Tau mice (TauP301S/TPS) and wild-type (WT) littermates of 3 months, 6 months, 9 months and 11 months. Quantitative analysis reveals increased microgliosis in Tau transgenic mice, preceding overt mature neurofibrillary tangles. Although the mature NFTs are detected scarcely from 9 months onwards and are more frequently from 11 to 12 months onwards (AT8 area; n = 6, TPS and WT of 3 and 6 months; n = 4, TPS of 9 months; n = 5, WT of 9 months; n = 3, TPS and WT of 11 months; two-way ANOVA with Dunnett’s multiple comparison post hoc test, ***p < 0,001, ****p < 0.0001), increased microglial activation is already detected from 6 months onwards (Iba1 area; n = 6, TPS and WT of 3 and 6 months; n = 4, TPS of 9 months; n = 5, WT of 9 months; n = 3, TPS and WT of 11 months; two-way ANOVA with Dunnett’s multiple comparison post hoc test, ***p < 0,001, ****p < 0,0001). b Representative images of Tau pathology assessed using anti-P-Tau (AT8; red) staining in hippocampal CA1 and frontal cortical regions of 11-month-old T +. ASC +/+ and T +.ASC−/− mice are presented. Quantitative analysis revealed decreased Tau pathology in non-exogenously seeded T +.ASC−/− mice compared to T +. ASC +/+ mice (n = 6, T +.ASC +/+; n = 6, T +.ASC−/−; Mann–Whitney t test, *p < 0.05)
Fig. 5 Age-dependent increase in microglial activation in Tau transgenic mice and decreased Tau pathology in ASC-deficient Tau mice indicate a contribution of the inflammasome in non-exogenously seeded Tau pathology. a Representative images of Iba1 (green) and anti-P-Tau (AT8; red) staining in hippocampal CA1 region of Tau mice (TauP301S/TPS) and wild-type (WT) littermates of 3 months, 6 months, 9 months and 11 months. Quantitative analysis reveals increased microgliosis in Tau transgenic mice, preceding overt mature neurofibrillary tangles. Although the mature NFTs are detected scarcely from 9 months onwards and are more frequently from 11 to 12 months onwards (AT8 area; n = 6, TPS and WT of 3 and 6 months; n = 4, TPS of 9 months; n = 5, WT of 9 months; n = 3, TPS and WT of 11 months; two-way ANOVA with Dunnett’s multiple comparison post hoc test, ***p < 0,001, ****p < 0.0001), increased microglial activation is already detected from 6 months onwards (Iba1 area; n = 6, TPS and WT of 3 and 6 months; n = 4, TPS of 9 months; n = 5, WT of 9 months; n = 3, TPS and WT of 11 months; two-way ANOVA with Dunnett’s multiple comparison post hoc test, ***p < 0,001, ****p < 0,0001). b Representative images of Tau pathology assessed using anti-P-Tau (AT8; red) staining in hippocampal CA1 and frontal cortical regions of 11-month-old T +. ASC +/+ and T +.ASC−/− mice are presented. Quantitative analysis revealed decreased Tau pathology in non-exogenously seeded T +.ASC−/− mice compared to T +. ASC +/+ mice (n = 6, T +.ASC +/+; n = 6, T +.ASC−/−; Mann–Whitney t test, *p < 0.05)CC BY · PubMed Central
Fig. 6 Data summary. Schematic summary of the data in relation with previously published data. Tau seeds, like aggregated Aβ (Halle et al.), activate NLRP3–ASC inflammasome following lysosomal uptake and dependent on Cathepsin B activation. NLRP3–ASC inflammasome activation contributes to exogenously and non-exogenously seeded Tau pathology, designating NLRP3–ASC as therapeutic target in Tauopathies. Previously, Heneka et al. showed that NLRP3–ASC inflammasome activation exacerbates amyloid pathology in vivo
Fig. 6 Data summary. Schematic summary of the data in relation with previously published data. Tau seeds, like aggregated Aβ (Halle et al.), activate NLRP3–ASC inflammasome following lysosomal uptake and dependent on Cathepsin B activation. NLRP3–ASC inflammasome activation contributes to exogenously and non-exogenously seeded Tau pathology, designating NLRP3–ASC as therapeutic target in Tauopathies. Previously, Heneka et al. showed that NLRP3–ASC inflammasome activation exacerbates amyloid pathology in vivoCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 103 references

Cited by

See all 447

Metadata

Authors
Stancu, I.-C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., Lodder, C., Brône, B., Huaux, F., Octave, J.-N., Terwel, D., & Dewachter, I.
Affiliations
  • Hasselt University (BE)
  • UCLouvain (BE)
Corresponding author
Dewachter, Ilse
Venue
Acta Neuropathologica
Published
2019-02-05
Volume
137
Issue
4
Pages
599-617
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2912579052
Cited by
447
References
103
Citations by year
2026: 42 · 2025: 65 · 2024: 76 · 2023: 77 · 2022: 69 · 2021: 55 · 2020: 45 · 2019: 17
FWCI
31.58
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (submittedVersion, other-oa)
  • Document Server@UHasselt (UHasselt) (submittedVersion, cc-by)
Funders
  • Fondation pour la Recherche Alzheimer (FRA-SAO Belgium)
  • Fonds De La Recherche Scientifique - FNRS
  • Agentschap Innoveren en Ondernemen (VLAIO)
  • Fonds Wetenschappelijk Onderzoek (G0C6819N)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tau aggregation, prion-like seeding, neuroinflammation, microglia, lysosomal sorting, MCC950, Alzheimer's disease, innate immunity, tau transgenic mice, neurofibrillary tangles
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Alzheimer Disease, Animals, Brain, Gliosis, Mice, Transgenic, tau Proteins, Microglia, Mice, CARD Signaling Adaptor Proteins, Interleukin-1beta, Inflammasomes, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. https://app.cochat.ai/papers/10.1007/s00401-018-01957-y
The paper
Stancu, I.-C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., Lodder, C., Brône, B., Huaux, F., Octave, J.-N., Terwel, D., & Dewachter, I. (2019). Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathologica. https://doi.org/10.1007/s00401-018-01957-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.